RESPIRATORY SYNCYTIAL VIRUS
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a shot during pregnancy shield babies from RSV?
⭐️ VACCINE ⭐️ CompletedThis study tested an mRNA vaccine (mRNA-1345) against respiratory syncytial virus (RSV) in 360 pregnant women. The goal was to see if the vaccine is safe for mothers and their babies, and whether it triggers an immune response that could protect infants after birth. Participants …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:07 UTC
-
Moderna's mRNA vaccine cocktail passes early safety check
⭐️ VACCINE ⭐️ CompletedThis study tested the safety and immune response of several Moderna mRNA vaccines for COVID-19, seasonal flu, RSV, and CMV in 308 healthy adults aged 18 to 75. Researchers monitored side effects and measured antibody levels after vaccination. The goal was to ensure the vaccines a…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:00 UTC
-
New RSV vaccine shows promise for seniors in korea
⭐️ VACCINE ⭐️ CompletedThis study tested an RSV vaccine in 378 older adults (60+) in Korea to see if it is safe and helps the body fight the virus. Participants received either the vaccine or a placebo and were monitored for side effects and immune response. The results showed the vaccine was well tole…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:03 UTC
-
New mRNA RSV vaccine shows promise for older adults in phase 3 trial
⭐️ VACCINE ⭐️ CompletedThis phase 3 study tested an mRNA vaccine called mRNA-1345 to protect against respiratory syncytial virus (RSV) in adults aged 50 and older. Over 3,300 participants received the vaccine alone, with a flu shot, or with a COVID-19 booster. The trial also looked at a booster dose on…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:07 UTC
-
RSV booster shot shows promise for seniors
Disease control CompletedThis study tested a new mRNA booster shot (mRNA-1345) in 507 adults aged 60 and older who had already received a licensed RSV vaccine at least a year earlier. The goal was to see if the booster is safe and boosts the immune system's ability to fight RSV. Researchers measured side…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New RSV shot protects thousands of babies from severe illness
Prevention CompletedThis study looked at how well a single dose of BEYFORTUS (nirsevimab) protects infants from serious RSV infections that require a doctor visit or hospital stay. Researchers followed nearly 50,000 babies during their first RSV season. The goal was to see if the shot reduces cases …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC